Rüst O, Rufli T, Forrer J
Schweiz Med Wochenschr. 1979 Dec 15;109(48):1914-20.
Two patients with extensive verrucae plantares have been treated successfully with the retinoic acid derivative Ro 10-9359. Both patients were practically unable to walk due to widespread involvement of the plantae pedium. In a second series of 12 patients with verrucae vulgares this form of therapy produced unsatisfactory results. In 2 further patients with verrucae plantares healing was achieved in one, and also in a patient with verrucae planae. A patient with verrucae periunguales did not react to the treatment. The dosage was gradually increased to above the normal value of 1.0 mg/kg body weight per day, according to individual tolerance. The aim was to reach a dose of over 1.5 mg/kg body weight per day. The side effects were therefore impressive and interruption or termination of therapy was often necessary. However, new side effects have not been observed with this high dosage and this new indication, apart from psoriasiform dermatitis and an intermittent vegetative disturbance, the latter without clear evidence of a causal relation to the Ro 10-9359 medication. Pathological liver values have not been observed. Treatment with retinoid appears to be appropriate in cases with verrucae plantares, especially where conventional methods do not prove satisfactory.
两名患有广泛跖疣的患者已成功接受视黄酸衍生物Ro 10-9359治疗。由于足底广泛受累，这两名患者实际上无法行走。在另一组12名患有寻常疣的患者中，这种治疗方式效果不理想。在另外两名患有跖疣的患者中，一名患者实现了治愈，一名扁平疣患者也实现了治愈。一名患有甲周疣的患者对治疗无反应。根据个体耐受性，剂量逐渐增加至高于每日1.0mg/kg体重的正常值，目标是达到每日超过1.5mg/kg体重的剂量。因此，副作用较为明显，常常需要中断或终止治疗。然而，除了银屑病样皮炎和间歇性植物神经功能紊乱（后者与Ro 10-9359用药无明确因果关系证据）外，尚未观察到这种高剂量和新适应症的新副作用。未观察到肝脏病理值异常。维甲酸治疗对于跖疣患者似乎是合适的，尤其是在传统方法效果不佳的情况下。
